How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

163 results for

Cyclic Lipopeptide

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Surfactin-Triggered Small Vesicle Formation of Negatively Charged Membranes: A Novel Membrane-Lysis Mechanism (PubMed)

vesicle formation thus appears to be linked to severe changes in membrane curvature and could be described by a two-step action: 1), peptide insertion into membranes because of favorable van der Waals forces between the rather rigid cyclic and lipophilic part of SF and lipid chains and 2), electrostatic repulsion between like charges borne by lipid headgroups and the negatively charged SF amino acids. This might provide the basis for a novel mode of action of negatively charged lipopeptides. (...) Surfactin-Triggered Small Vesicle Formation of Negatively Charged Membranes: A Novel Membrane-Lysis Mechanism The molecular mode of action of the lipopeptide SF with zwitterionic and negatively charged model membranes has been investigated with solid-state NMR, light scattering, and electron microscopy. It has been found that this acidic lipopeptide (negatively charged) induces a strong destabilization of negatively charged micrometer-scale liposomes, leading to the formation of small

Full Text available with Trip Pro

2008 Biophysical journal

122. Regulation of Cyclic Lipopeptide Biosynthesis in Pseudomonas fluorescens by the ClpP Protease (PubMed)

Regulation of Cyclic Lipopeptide Biosynthesis in Pseudomonas fluorescens by the ClpP Protease Cyclic lipopeptides produced by Pseudomonas species exhibit potent surfactant and broad-spectrum antibiotic properties. Their biosynthesis is governed by large multimodular nonribosomal peptide synthetases, but little is known about the genetic regulatory network. This study provides, for the first time, evidence that the serine protease ClpP regulates the biosynthesis of massetolides, cyclic (...) regulation of massetolide biosynthesis operates independently of regulation by the GacA/GacS two-component system. The role of amino acid metabolism and the putative mechanisms underlying ClpP-mediated regulation of cyclic lipopeptide biosynthesis, swarming motility, and growth in P. fluorescens are discussed.

Full Text available with Trip Pro

2008 Journal of bacteriology

123. Treatment of staphylococcal infections with cyclic lipopeptides. (PubMed)

Treatment of staphylococcal infections with cyclic lipopeptides. Daptomycin is the first of a new class of antibiotics, the cyclic lipopeptides, for which a novel mechanism of action is hypothesised. Owing to its mode of action, daptomycin is rapidly bactericidal without being bacteriolytic, is active against static- and growing-phase bacteria, and has a low resistance rate in vitro. Phase III clinical trials have demonstrated that daptomycin is as effective as standard therapy

Full Text available with Trip Pro

2008 Clinical Microbiology and Infection

124. Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever. (PubMed)

Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever. Daptomycin is the first antibacterial agent of the cyclic lipopeptides with in vitro bactericidal activity against gram-positive organisms, including vancomycin-resistant enterococci, methicillin-resistant staphylococci, and glycopeptide-resistant Staphylococcus aureus. The pharmacokinetics of daptomycin were determined in 29 adult oncology patients with neutropenic fever. Serial blood samples were drawn at 0, 0.5, 1

Full Text available with Trip Pro

2008 Antimicrobial Agents and Chemotherapy

125. Daptomycin: rationale and role in the management of skin and soft tissue infections. (PubMed)

Daptomycin: rationale and role in the management of skin and soft tissue infections. The emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide tolerance in S. aureus has underlined the importance of the newer anti-MRSA agents, particularly in the management of complicated skin and soft tissue infections (cSSTIs). The novel cyclic lipopeptide antibiotic daptomycin shows marked in vitro cidality against MRSA compared with both vancomycin

Full Text available with Trip Pro

2008 Journal of Antimicrobial Chemotherapy

126. Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy

Transplant 2000;25:853-9. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51. Indexing Status Subject indexing assigned by NLM MeSH Adult; Amphotericin B /administration & Antifungal Agents /administration & Antineoplastic Agents /therapeutic use; Cohort Studies; Cost-Benefit Analysis; Echinocandins; Fluconazole /administration & Humans; Leukemia, Myeloid, Acute /drug therapy; Lipopeptides (...) ; Lipoproteins /administration & Mycoses /drug therapy; Opportunistic Infections /complications /drug therapy; Peptides, Cyclic /administration & dosage /economics; dosage /economics; dosage /economics; dosage /economics; dosage /economics AccessionNumber 22006007591 Date bibliographic record published 31/10/2006 Date abstract record published 31/10/2006 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York Homepage Options Print

2006 NHS Economic Evaluation Database.

127. Cubicin - daptomycin

problems due to acquisition of multiple resistance determinants. Therefore, there is a need for additional agents that might be clinically active against these difficult to treat pathogens to the existing antibiotic armamentarium. The present application for marketing authorisation of CUBICIN (350 or 500 mg powder for concentrate for solution for infusion) is made under Article 8.3 (i) and concerns a new active substance, daptomycin. Daptomycin is a novel cyclic lipopeptide derived from a natural (...) pharmacodynamics Daptomycin is a novel cyclic lipopeptide antibiotic derived from the fermentation of a strain of Streptomyces roseosporus. Daptomycin inserts directly into the cytoplasmic membrane of Gram-positive cells (aerobes and anaerobes). This action is calcium-dependent and results in a rapid depolarisation of the membrane, thus giving rise to the efflux of potassium ions. Bacterial DNA, RNA and protein synthesis is rapidly stopped with subsequent cell death that does not depend upon lysis

2006 European Medicines Agency - EPARs

128. Use of PCR-Targeted Mutagenesis To Disrupt Production of Fusaricidin-Type Antifungal Antibiotics in Paenibacillus polymyxa (PubMed)

of bacterial sporulation. The fusaricidins are a family of lipopeptide antibiotics consisting of a beta-hydroxy fatty acid linked to a cyclic hexapeptide. Using a reverse genetic approach based on conserved motifs of nonribosomal peptide synthetases, a DNA fragment that appears to encode the first two modules of the putative fusaricidin synthetase (fusA) was isolated from PKB1. To confirm the involvement of fusA in production of fusaricidins, a modified PCR targeting mutagenesis protocol was developed

Full Text available with Trip Pro

2007 Applied and environmental microbiology

129. Massetolide A Biosynthesis in Pseudomonas fluorescens (PubMed)

Massetolide A Biosynthesis in Pseudomonas fluorescens Massetolide A is a cyclic lipopeptide (CLP) antibiotic produced by various Pseudomonas strains from diverse environments. Cloning, sequencing, site-directed mutagenesis, and complementation showed that massetolide A biosynthesis in P. fluorescens SS101 is governed by three nonribosomal peptide synthetase (NRPS) genes, designated massA, massB, and massC, spanning approximately 30 kb. Prediction of the nature and configuration of the amino

Full Text available with Trip Pro

2007 Journal of bacteriology

130. Clinical Progression of Methicillin-Resistant Staphylococcus aureus Vertebral Osteomyelitis Associated with Reduced Susceptibility to Daptomycin (PubMed)

Clinical Progression of Methicillin-Resistant Staphylococcus aureus Vertebral Osteomyelitis Associated with Reduced Susceptibility to Daptomycin Daptomycin, a novel cyclic lipopeptide antibiotic, exhibits rapid bactericidal activity in vitro against most clinically relevant gram-positive organisms, including drug-resistant pathogens. Herein we describe a patient in whom methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin was responsible for bacteremia

Full Text available with Trip Pro

2005 Journal of clinical microbiology

131. Neurotrophic peptide aldehydes: Solid phase synthesis of fellutamide B and a simplified analog (PubMed)

Neurotrophic peptide aldehydes: Solid phase synthesis of fellutamide B and a simplified analog A combination of solid phase and solution phase synthetic methods have been used to complete the total synthesis of the neurotrophic lipopeptide aldehyde fellutamide B (2). The beta-hydroxy aliphatic tail was prepared by regioselective reductive opening of a cyclic sulfate, and later coupled to a solid phase resin. The synthetic compound was then examined in cytotoxicity and nerve growth factor (NGF

Full Text available with Trip Pro

2006 Bioorganic & medicinal chemistry letters

132. The Heat Shock Genes dnaK, dnaJ, and grpE Are Involved in Regulation of Putisolvin Biosynthesis in Pseudomonas putida PCL1445 (PubMed)

The Heat Shock Genes dnaK, dnaJ, and grpE Are Involved in Regulation of Putisolvin Biosynthesis in Pseudomonas putida PCL1445 Pseudomonas putida PCL1445 produces two cyclic lipopeptides, putisolvins I and II, which possess surfactant activity and play an important role in biofilm formation and degradation. In order to identify genes and traits that are involved in the regulation of putisolvin production of PCL1445, a Tn5luxAB library was generated and mutants were selected for the lack

Full Text available with Trip Pro

2005 Journal of bacteriology

133. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. (PubMed)

Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. Endocarditis and bacteraemia are devastating infections with high mortality. Gram-positive cocci are the most commonly isolated pathogens. In an era of multidrug-resistant pathogens, the evaluation of new treatment options is important. Daptomycin is a cyclic lipopeptide that is active against most of these pathogens. Furthermore, it is a bactericidal antibiotic, a factor

Full Text available with Trip Pro

2007 The Journal of antimicrobial chemotherapy

134. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. (PubMed)

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive pathogens, including organisms that are resistant to methicillin, vancomycin, and other currently available agents. Daptomycin (4 mg/kg intravenously [iv] every 24 h for 7-14 days) was compared with conventional antibiotics

Full Text available with Trip Pro

2004 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

135. Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient. (PubMed)

Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient. The rate of infection in patients who require ventricular assist devices is estimated at more than 35%. Infections with multi-resistant organisms such as methicillin-resistant Staphylococcus aureus in ventricular assist device recipients are often difficult to treat and present a high mortality rate. Daptomycin is a new cyclic lipopeptide antibiotic

2007 Annals of Thoracic Surgery

136. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. (PubMed)

advantages over bacteriostatic therapy in certain infections. Daptomycin, the first of the cyclic lipopeptides, shows rapid bactericidal activity against S. aureus, including strains tolerant or resistant to other agents. This review outlines the methods by which bactericidal and bacteriostatic properties are defined and tested, discusses the potential importance of bactericidal therapy in MRSA and other infections and examines the potential role of daptomycin in treatment.

Full Text available with Trip Pro

2006 Journal of Antimicrobial Chemotherapy

137. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. (PubMed)

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Daptomycin is a novel cyclic lipopeptide antibiotic that provides rapid bactericidal activity against gram-positive pathogens in vitro, including methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus, vancomycin-resistant S. aureus, penicillin-resistant Streptococcus pneumoniae, and ampicillin- and vancomycin-resistant enterococci. The United States Food and Drug

Full Text available with Trip Pro

2004 Clinical Infectious Diseases

138. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. (PubMed)

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. Increasing antimicrobial resistance among bacterial pathogens has prompted attempts to develop new antimicrobial agents active against multidrug-resistant Gram-positive pathogens.To evaluate the in vitro activity of daptomycin against a worldwide collection of clinical bacterial isolates.Daptomycin is a novel cyclic lipopeptide recently approved by the United States Food and Drug Administration

Full Text available with Trip Pro

2004 Journal of Antimicrobial Chemotherapy

139. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. (PubMed)

In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. The activities of daptomycin, a cyclic lipopeptide, and eight other agents were determined against 338 strains of gram-positive anaerobic bacteria and corynebacteria by the NCCLS reference agar dilution method with supplemented brucella agar for the anaerobes and Mueller-Hinton agar

Full Text available with Trip Pro

2003 Antimicrobial Agents and Chemotherapy

140. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. (PubMed)

Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. Infection due to methicillin-resistant Staphylococcus aureus (MRSA) is increasingly common in nosocomial and community settings. Daptomycin is a cyclic lipopeptide anti-infective with activity against MRSA, approved for treatment of complicated skin and skin structure infections. Daptomycin may be useful in systemic or local treatment of chronic osteomyelitis.We measured mechanical strength of daptomycin

Full Text available with Trip Pro

2006 Journal of Antimicrobial Chemotherapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>